> Support continues for extending hormonal therapy in early-stage hormone receptor-positive breast cancers

Support continues for extending hormonal therapy in early-stage hormone receptor-positive breast cancers

  • 12/07/18
general_content

Findings announced at the San Antonio Breast Cancer Symposium offer more evidence that continuing hormonal therapy after five years prevents recurrences.

Thursday morning’s presentations at the 2018 San Antonio Breast Cancer Symposium focused on treatments for hormone receptor-positive breast cancers. Three studies looked at how hormonal therapy is given, focusing on how long people with early-stage disease should take hormonal therapy and at what dose. The SOLAR-1 trial looked at a new targeted therapy for people with metastatic breast cancer whose disease has a mutation in the PI3K pathway, which occur in 40 percent of hormone receptor-positive breast cancers.

[class^="wpforms-"]
[class^="wpforms-"]
[item.name]
[item.name]
[item]
[item]